Current trends in chemotherapy of tuberculosis

Indian Journal of Medical Research

Volumn 120, Issue 4, 2004, Pages 398-417

  Jawahar, M Shaheed ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Adverse reaction; Chemotherapy; Multidrug resistance; Short course; Tuberculosis

Indexed keywords

ACETYLSALICYLIC ACID; AMINOSALICYLIC ACID; ANTACID AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; PYRIDOXINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANOREXIA; ARTHRALGIA; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BURNING SENSATION; CHILD; CLINICAL TRIAL; DISEASE CONTROL; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; EXTRAPULMONARY TUBERCULOSIS; FLU LIKE SYNDROME; GROWTH INHIBITION; HEALTH PROGRAM; HEARING IMPAIRMENT; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INDIA; JAUNDICE; LIVER DYSFUNCTION; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PRURITUS; PURPURA; REVIEW; SEIZURE; SHOCK; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION;

ADULT; CHILD; COMMUNICABLE DISEASE CONTROL; DEVELOPING COUNTRIES; DIRECTLY OBSERVED THERAPY; DRUG THERAPY, COMBINATION; HUMANS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 8644268071     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Waksman SA. Suppressive effect of streptomycin on the growth of tubercle bacilli in laboratory animals. Am J Public Health 1944; 34 : 358.
2. Hinshaw HC, Feldman WH. Streptomycin in the treatment of clinical tuberculosis; a preliminary report. Proc Staff Meeting Mayo Clin 1945; 20 : 313-8.
3. Dormandy, T. The White Death: a history of tuberculosis. Hambledon and London 2001.
4. Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981; 75: 331-57.
5. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 : S231-79.
6. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1959; 21 : 51-144.
7. Kamat SR, Dawson JJY, Devadatta S, Fox W, Janardhanam B, Radhakrishna S, et al. A controlled study of the influence of segregation of tuberculosis patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ 1966; 34 : 517-32.
8. Fox W. Realistic chemotherapeutic policies for tuberculosis in the developing countries. Br Med J 1964; 1 : 135-42.
9. East African/ British Medical Research Councils. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-85.
10. East African/British Medical Research Councils Study. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977; 116 : 3-8.
11. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Tubercle 1978; 59: 287-97.
12. Dickinson JM, Mitchison DA. Observation in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 1970; 51 : 389-96.
13. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121 : 939-49.
14. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: S771-81.
15. Tripathy SP. Short course chemotherapy of pulmonary tuberculosis. Indian J Tuberc 1982; 29 : 3-13.
16. Tripathy SP. Relapse in tuberculosis. Indian J Tuberc 1981; 28 : 45-57.
17. Second East African/ British Medical Research Councils Study. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1974; 2 : 1100-6.
18. Hong Kong Chest Service/ British Medical Research Councils. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1978; 118 : 219-27.
19. East African/British Medical Research Councils. Controlled clinical trial of 4 short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis (third report). Lancet 1974; 2 : 237-40.
20. Hong Kong Chest Service/ British Medical Research Councils. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. The results upto 24 months. Tubercle 1979; 60 : 201-10.
21. Dickinson JM, Mitchison DA. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 1966; 47 : 370-80.
22. Dickinson JM, Mitchison DA. Short-term intermittent chemotherapy of experimental tuberculosis in the guinea pig. Tubercle 1966; 47 : 381-93.
23. Dickinson JM, Mitchison DA. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 1970; 51 : 82-94.
24. Tuberculosis Chemotherapy Centre, Madras. Intermittent treatment of pulmonary tuberculosis. A concurrent comparison of twice-weekly isoniazid plus streptomycin and daily isoniazid plus p-aminosalicylic acid in the domiciliary treatment. Lancet 1963; 1 : 1078-80.
25. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Organ 1964; 31 : 247-71.
26. Hong Kong Chest Service/BMRC. Controlled trial of 6-and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong: the results up to 30 months. Am Rev Respir Dis 1977; 115 : 727-35.
27. Hong Kong Chest Service/BMRC. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; 1 : 171-4.
28. Balasubramanian R. Fully intermittent six month regimens for pulmonary tuberculosis in south India. Indian J Tuberc 1991; 38 : 51-3.
29. World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes, 3rd ed. Geneva : World Health Organization, 2003 (WHO/CDS/TB/2003.313).
30. World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes, 2nd ed. Geneva: World Health Organization, 1997 (WHO/TB/97.220).
31. World Health Organisation. Tuberculosis Programme Review India 1992. Geneva: World Health Organisation, 1995 (WHO/TB/95/186).
32. Technical guidelines for tuberculosis control. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 1997.
33. Garcia-Rodriquez JA, Gomez-Garcia AC. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32 : 797-808.
34. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 : 827-33.
35. Tuberculosis Research Centre. Shortening Short Course Chemotherapy: A randomized clinical trial for the treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002; 49 : 27-38.
36. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in south India. Am Rev Respir Dis 1986; 134 : 27-33.
37. Herbert D, Paramasivan CN, Venkatesan P, Kubendran G, Prabhakar R, Mitchison DA. Evaluation of bactericidal action of ofloxacin and sulbactum-ampicillin alone and in combination with rifampicin and isoniazid on M. tuberculosis in vitro. Antimicrob Agents Chemother 1996; 40 : 2296-9.
38. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al. A multicentre study of the early bactericidal activity of anti- tuberculosis drugs. J Antimicrob Chemother 2000; 45 : 859-70.
39. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45 : 3482-6.
40. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47 : 653-7.
41. Jawahar MS, Sivasubramanian S, Vijayan VK, Ramakrishnan CV, Paramasivan CN, Selvakumar V, et al. Short course chemotherapy for tuberculous lymphadenitis in children. BMJ 1990; 301: 359-62.
42. Jawahar MS. Scrofula revisited: An update on the diagnosis and management of tuberculosis of superficial lymphnodes. Indian J Paediatr 2000; 67 (Suppl) : SS2: S28-S33.
43. Ramachandran P, Duraipandian M, Nagarajan M, Prabhakar R, Ramakrishnan CV, Tripathy SP. Three chemotherapy studies of tuberculous meningitis in children. Tubercle 1986; 67: 17-29.
44. Indian Council of Medical Research/ British Medical Research Council Working Party in south India. Controlled clinical trial of short course regimens of chemotherapy in patients receiving ambulatory treatment or undergoing radical surgery for tuberculosis of the spine. Indian J Tuberc 1989; 36 (Suppl) : 1-21.
45. Rajeswari R, Balasubramanian R, Venkatesan P, Sivasubramanian S, Soundarapandian S, Shanmugasundaram TK, et al. Short-course chemotherapy in the treatment of Pott's paraplegia: report on five-year follow-up. Int J Tuberc Lung Dis 1997; 1 : 152-8.
46. Balasubramanian R, Nagarajan M, Balambal R, Tripathy SP, Sundararaman R, Venkatesan P, et al. Randomized clinical trial of short course chemotherapy in abdominal tuberculosis: a five-year report. Int J Tuberc Lung Dis 1997; 1 : 44-51.
47. Rajeswari R, Sivasubramanian S, Balambal R, Parthasarathy R, Ranjani R, Santha T, et al. A controlled clinical trial of short-course chemotherapy for tuberculoma of the brain. Int J Tuberc Lung Dis 1995; 76 : 111-7.
48. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolons as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; ii : 1418-22.
49. Managing the Revised National Tuberculosis Programme in your area: A Training Course. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2000.
50. Centers for Disease Control and Prevention. Nosocomial transmission of multi drug-resistant tuberculosis among HIV infected persons: Florida and New York, 1988-1991. Morb Mortal Wkly Rep 1991; 40 : 585-91.
51. Neville K, Bromberg A, Bromberg R, Bonk S, Hanna BA, Rom WN. The third epidemic - multidrug-resistant tuberculosis. Chest. 1994; 105 : 45-8.
52. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338 : 1641-9.
53. Venkataraman P, Paramasivan CN. Drug resistance in tuberculosis and issues related to multidrug resistance in planning for TB control in India. Health Administrator 2003; 15 : 127-36.
54. Iseman MD: Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329 : 784-91.
55. Goble M, Iseman MD, Madsen LA, Waite I, Ackerson L, Horsburgh CR: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328 : 527-32.
56. Barnes PF, Barrows SA. Tuberculosis in the 1990s. Ann Intern Med 1993; 119 : 400-10.
57. Jawahar MS. Multi-drug resistant tuberculosis. ICMR Bull 1999; 29 : 105-14.
58. Bacteriological aspects of the National Register of drug resistant tuberculosis in it's first two years. Marks J. Monthly Bull Ministry Health (London) 1965; 24 : 2.
59. Yew WW, Chan CH. Drug resistant tuberculosis in the 1990s. Eur Respir J 1995; 8 : 1184-92.
60. Kir A, Tahaoglu K, Okur E, Hatipoglu T. Role of surgery in multi-drug-resistant tuberculosis: results of 27 cases. Eur J Cardiothorac Surg 1997; 12 : 531-4.
61. Pomerantz M, Brown JM. Surgery in the treatment of multidrug-resistant tuberculosis. Clin Chest Med. 1997; 18 : 123-30.
62. Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi M. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis 2002; 40 : 690-6.
63. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163 : 1009-21.
64. www.NACO.nic.in; date accessed 27th July 2004.
65. Paranjape RS, Tripathy SP, Menon PA, Mehendale SM, Khatavkar P, Joshi DR, et al. Increasing trend of HIV seroprevalence among pulmonary tuberculosis Patients in Pune, India. Indian J Med Res 1997; 106 : 207-11.
66. Sharma SK, Aggarwal G, Seth P, Saba PK. Increasing HIV seropositivity among adult tuberculosis patients in Delhi. Indian J Med Res 2003; 117 : 239-42.
67. Ramachandran R, Datta M, Subramani R, Baskaran G, Paramasivan CN, Swaminathan S. Seroprevalence of human immunodeficiency virus (HIV) infection among tuberculosis patients in Tamil Nadu. Indian J Med Res 2003; 118 : 147-51.
68. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 2004; 364 : 69-82.
69. Toossi Z. Virological and immunological impact of human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188 : 1146-55.
70. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393 : 537-44.
71. Chopra P, Meena LS, Singh Y. New drug targets for Mycobacterium tuberculosis. Indian J Med Res 2003; 117 : 1-9.
72. Freire M, Roscigno G. Joining forces to develop weapons against tuberculosis: together we must. Bull World Health Organ 2002; 80 : 429.